P2Y2 receptor desensitization on single endothelial cells.

Department of Physiology, Universidad Central del Caribe, Bayamon, Puerto Rico.
Endothelium (Impact Factor: 1.91). 01/2008; 15(1):43-51. DOI: 10.1080/10623320802092294
Source: PubMed

ABSTRACT Receptor desensitization, or decreased responsiveness of a receptor to agonist stimulation, represents a regulatory process with the potential to have a significant impact on cell behavior. P2Y(2), a G-protein-coupled receptor activated by extracellular nucleotides, undergoes desensitization at many tissues, including the vascular endothelium. Endothelial cells from a variety of vascular beds are normally exposed to extracellular nucleotides released from damaged cells and activated platelets. The purpose of the present study was to compare P2Y(2) receptor desensitization observed in endothelial cells derived from bovine retina, a model of microvascular endothelium, and human umbilical vein endothelial cells (HUVECs), a model of a large blood vessel endothelium. P2Y(2) receptor desensitization was monitored by following changes in UTP-stimulated intracellular free Ca(2 +) in single cells using fura-2 microfluorometry. Both endothelial cell models exhibited desensitization of the P2Y(2) receptor after stimulation with UTP. However, the cells differed in the rate, dependence on agonist concentration, and percentage of maximal desensitization. These results suggest differential mechanisms of P2Y(2) receptor desensitization and favors heterogeneity in extracellular nucleotide activity in endothelial cells according to its vascular bed origin.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Purinergic signaling plays important roles in control of vascular tone and remodeling. There is dual control of vascular tone by ATP released as a cotransmitter with noradrenaline from perivascular sympathetic nerves to cause vasoconstriction via P2X1 receptors, whereas ATP released from endothelial cells in response to changes in blood flow (producing shear stress) or hypoxia acts on P2X and P2Y receptors on endothelial cells to produce nitric oxide and endothelium-derived hyperpolarizing factor, which dilates vessels. ATP is also released from sensory-motor nerves during antidromic reflex activity to produce relaxation of some blood vessels. In this review, we stress the differences in neural and endothelial factors in purinergic control of different blood vessels. The long-term (trophic) actions of purine and pyrimidine nucleosides and nucleotides in promoting migration and proliferation of both vascular smooth muscle and endothelial cells via P1 and P2Y receptors during angiogenesis and vessel remodeling during restenosis after angioplasty are described. The pathophysiology of blood vessels and therapeutic potential of purinergic agents in diseases, including hypertension, atherosclerosis, ischemia, thrombosis and stroke, diabetes, and migraine, is discussed.
    Pharmacological reviews 01/2014; 66(1):102-192. DOI:10.1124/pr.113.008029 · 18.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Each segment of the vascular system has its own function, based on its location in the body. The endothelial cells lining these vascular segments are an intrinsic part of this segmental variation, and it is not surprising that throughout the vascular bed they have a highly heterogenic appearance. This chapter starts with a description of the heterogenic phenotype of endothelial cells in the body in quiescent conditions. Focus is next on endothelial engagement in inflammatory processes and how the microvascular endothelial cells in the different organs and within an organ respond to tumor necrosis factor a, interleukin-1, and lipopolysaccharide as inflammatory stimuli. Studies on endothelial responsiveness both in vitro in culture systems and in vivo in the intact body are discussed. From a pharmacological point of view, knowledge of the molecular basis of heterogeneity in endothelial cell behavior will be critical for successful drug development to counteract endothelial cell engagement in disease. This chapter therefore concludes with a short overview of technological advancements that may assist in unveiling the mechanisms responsible. When applied to address microvascular endothelial heterogeneity, major steps forward in endothelial biomedicine are anticipated that will assist in defining the right molecular targets for the microvascular segments involved in the pathology under study.
    09/2010: pages 15-35;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Microvascular endothelial cells play an essential role in inflammatory diseases. Functional heterogeneity between microvascular segments in normal organ homeostasis has been appreciated for a long time, and more recent studies have revealed heterogeneity in endothelial reactivity to inflammatory stimuli as well. This review summarizes the state-of-the-art knowledge regarding endothelial cell responses to the proinflammatory cytokines tumor necrosis factor alpha, interleukin-1beta, and the bacterial product lipopolysaccharide. It focuses on similarities and differences in reactivity between endothelial cell subsets in vitro and endothelial cells in their pathophysiological environment in vivo, and culminates into a mainly theoretical model of possible intracellular control mechanisms that can assist to ultimately explain the molecular causes of endothelial heterogeneity. The last part of this review contains some pharmacological considerations, and, with the aim to further unravel the molecular basis of in vivo endothelial heterogeneity, descriptions of new techniques that will be essential to achieve this.
    Seminars in Thrombosis and Hemostasis 04/2010; 36(3):246-64. DOI:10.1055/s-0030-1253448 · 3.69 Impact Factor